University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Chloe Atreya, M.D., Ph.D.

Gastrointestinal cancer specialist

Dr. Chloe Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. Her research focuses on the interplay of tumor genetics and a patient's response to therapies for colorectal cancer, with the goal of improving patient outcomes by personalizing therapy.

Atreya received her medical degree and Ph.D. in pharmacology at Yale University. Subsequently, she completed her internship and residency in internal medicine at University of Washington, Seattle and fellowship in medical oncology at UCSF, where she is now assistant clinical professor. Atreya is the recipient of numerous prestigious awards, including the American Cancer Society Postdoctoral Fellowship, Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. She is a member of the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for Clinical Trials in Oncology, Gastrointestinal Committee.

Clinics

Gastrointestinal Surgery and Oncology Clinic
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone (Pancreatic Cancer): (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

More about Chloe Atreya

Education

Yale University School of Medicine 2005

Residencies

University of Washington Medical Center, Internal Medicine 2008

Fellowships

UCSF Medical Center, Medical Oncology 2010

Selected Research and Publications

  1. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
  2. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS. . Cancer Medicine. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. 2013.
  3. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506.
  4. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
  5. Atreya CE, Ostrem JM, and Kelley RK. Personalized Medicine in Oncology. KRAS and Colorectal Cancer: Shades of Gray. 2012; 6(1).
  6. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
  7. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.